England’s health technology assessment (HTA) institute, NICE, has concluded that a severity modifier introduced in 2022 as a replacement for its previous end-of-life modifier has resulted in a higher proportion of drugs being recommended for use on the National Health Service.
Key Takeaways
-
England's NICE reported a positive impact on the reimbursement of medicines from its severity modifier, which was introduced in 2022 and replaced the end-of-life modifier.
-
However, the ABPI argued that the severity modifier has hindered patient access in some cases, and blamed the UK government for restricting NICE's spending
For this reason, NICE’s board